Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — 9M 2022 Earnings Presentation
44 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2022
Slide 1: 9M2022 Results Update
9M2022 Results Update
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: List of Figures
LIST OF FIGURES Corporate Overview 04 Indonesia Healthcare Market 18 Revenue 34 Global Trend in Diagnostic Lab Company Highlight 05 19 Visit and Revenue per Visit 35 Market Company History 06 Growth Strategy 20 Volume and Test per Visit 36 Investment Highlight 07 Leader in Next Gen Technology 21 Bre
Slide 4: Corporate Overview
1 CORPORATE OVERVIEW 4
Slide 5: Company Highlight
• More than 49 years IDR 1.58 Trillion experience in Clinical Lab Industry since 1973 9M2022 Revenue (-20.6% yoy; 3yrs CAGR +8.4%) • Has the most recognized Brand in Indonesia >2.0 Million • Largest private 9M2022 Visit (-22.0% yoy; 3yrs CAGR +4.2%) independent clinical lab chain by size of network
Slide 6: Strong Track Record in Clinical Laboratory Testing
Strong Track Record in Clinical Laboratory Testing • Establishment of Prodia Became the first Established professional Partnerships National Referral Lab, Established clinical laboratory management team with National the first Indonesian lab Prodia ChildLab in Indonesia to Scholarships given t
Slide 7: Investment Highlight
2 INVESTMENT HIGHLIGHT 7
Slide 8: Largest Network & Market Share in Independent Clinical Lab Industry
Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2020 & 2021) (Gross Revenue, in Billion IDR) 3YRS CAGR 39.5% 37.9% 26.0% 7,225 3YRS CAGR 2021 27.8% 2020 33.1% 4,551 4,874 23.9% 2,737 32.7% 1,782 1
Slide 9: Operational Track Record
Operational Track Record VISITS REVENUE CAGR CAGR 7.7% 14.3% Prodia has generated continuous revenue growth 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 and increasing number of visits that supported REVENUE PER VISIT Company’s profitability EBITDA CAGR 6.1% CAGR 34.4% 9 2016 2017 201
Slide 10: Comprehensive Service Offering with Multiple Customer Segments
Comprehensive Service Offering with Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics One-stop shop, offering the most Esoteric Testing Referral Lab Services Doctor Consultation comprehensive Predictive, Preventive, General Medical Preventive Treatment range of clin
Slide 11: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model 4 Referral Labs in Jakarta, Significant Surabaya, Medan, Makassar Economies of Scale Achieved “Hub and spoke” model offers scalable platform reducing Centralized information Prodia Clinical Labs, Prodia Referral with integrated IT turnaround time and cost Hospit
Slide 12: Strong Relationship with Medical Community
Strong Relationship with Medical Community Strong relationships through the work of more Introduced new tests, such as NIPT ProSafe, Amino Acid Profile, than 500 Marketing and Laboratory Fatty Acid Profile, CArisk, DIArisk, Liquid biopsy EGFR Mutation, New Information Service personnel Born Screenin
Slide 13: One of the Largest Digital Healthcare Platform in Indonesia
One of the Largest Digital Healthcare Platform in Indonesia Walk-in Apps Doctor Referral Apps Prodia Mobile Prodia Mobile for Doctor More than 1.2 mio Launched in April 2022 downloaders • Online Referral • Online registration • Online Chat • Online Payment 213.7% Patient’s Growth • Online Results >2
Slide 14: Experienced Senior Leadership and Management Team
Experienced Senior Leadership and Management Team Professional Management Team with Strong Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 48 Experience 48 Experience 38 Experience 47 Experience 30 Experience Andi Gunawan Endang Joseph Fellipus
Slide 15: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 15% 28% Distributor for Contract Research, therapy Distributor for medical Research and banking of healthcare equipment Organization stem cell products PT Prodia Widyahusada Tbk Nationwide Outlet Network across Indonesia Occupa
Slide 16: Market Overview & Growth Strategy
3 MARKET OVERVIEW & GROWTH STRATEGY 16
Slide 17: Indonesia Economic Outlook
Indonesia Economic Outlook 5.0% – 5.4% Indonesia’s GDP Growth Projection for 2022 Indonesia’s economic has GDP Growth Projection 2022 & 2023 proven to be more 2022 2023 resilient to global Indonesia’s Govt’ 5.0% - 5.2% 5.3% recession supported by World Bank 5.1% 5.3% well-controlled pandemic Organiz
Slide 18: Indonesia Healthcare Market
Indonesia Healthcare Market Indonesia Healthcare Market Indonesia Digital Healthcare Market (IDR Trillion) (IDR Trillion) 700.0 624.2 50.0 45.5 585.3 600.0 548.3 509.1 40.0 462.7 435.1 472.4 500.0 423.3 435.0 28.0 400.0 30.0 300.0 20.0 17.2 200.0 10.6 8.1 10.0 3.9 5.9 100.0 0.9 2.3 - - 2017 2018 201
Slide 19: Company's Growth Strategy
Company’s Growth Strategy Strengthen digital capabilities to Expand our presence and enable business growth grow our network of outlets in both physical and digital Develop data & analytics channel in Indonesia Near- capabilities to create business values A term Upgrade existing clinical Enhance int
Slide 20: Global Trend in Diagnostic Lab Market
Global Trend in Diagnostic Lab Market 1 2 3 4 Creating Digital Strategic Customer Centric Development of Ecosystem Partnership and Model testing technology Collaboration and AI Healthcare Platform B2B Business Expansion Digital Customer Journey Preventive Genomics Electronic Health Record Market Con
Slide 21: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me
Slide 22: Our Response to Business Landscape
Our Response to Business Landscape • Upgrade Prodia Mobile • Wellness Package • Prodia Mobile for Doctor • Genomic Tests • ProdiaLink for External Referral • Ethos – HS platform • Prodia in Your Car Lab Market: Digital Service Development Product and Lab Testing Innovation New Players Coming • Added
Slide 23: Prodia Sustainable Action Plan
Prodia Sustainable Action Plan Prodia Sustainable Action Plan is an initiative and effort made by Prodia in order to achieve sustainable business growth so as to create added value for stakeholders including shareholders, customers, medical personnel, regulators, the communities and the environment.
Slide 24: Business Update
4 BUSINESS UPDATE 24
Slide 25: Deliver Solution for Customer Needs
DELIVER SOLUTION FOR CUSTOMER NEEDS Respond to People Behavior Changing and Customer’s Voice Services & Lab Facilities • Safety, Quality & Cleanliness Product Innovation of Our Lab/Facilities/Staffs • Complete Testing from Routine to Esoteric • Prodia Mobile Test, Genomics Testing • Home/Office Serv
Slide 26: Customer Centric Model: New Innovation & Enhancement
Customer Centric Model Prodia in your Car New Innovation & Enhancement Service Prodia Home Customer Service Centric Tele-Consultation Tele-Radiology • General Practitioners • Clinical Pathologists Tele-Health* • Internist ProdiaLink • Clinical Nutritionist • Sport Medicine
Slide 27: Digital Transformation to Fulfill Customer Needs
Digital Transformation to Fulfill Customer Needs Prodia Mobile apps provides online registration/booking, online payment, online results, chat with doctors, and home service booking. > > Prodia has enhanced its digital platform services New Prodia Mobile Ver. 3.3.0 – Updated in April 2022 27
Slide 28: Digital Apps 9M2022 Highlights
Digital Apps 9M2022 Highlights Digital Collaboration Prodia Mobile downloader order revenue 116.1% 213.7% 219.8% 1.2 mio downloaders 9.7% to total visit 11.9% to total revenue online results new customer users revenue per visit 22% higher vs 22% new revenue 48.3% regular customer acquisitions 83% to
Slide 29: Digital Diagnostic Partner for Doctors
Digital Diagnostic Partner for Doctors Prodia Mobile for Doctor apps assist doctors to create testing referral to all Prodia’s Lab Services, provides live chat and manage their patient’s online health report. Launched in April 2022 >2,900 downloaders >1,100 active doctors (chat & referral) 29
Slide 30: Home Service Highlights
Home Service Highlights 9M21-9M22 growth +15.4% Contribution to 4.2% 4.5% 150.0 Total Revenue 6.2% 80.04.0% 7.0% 3.5% 4.3% 100.0 60.03.0% 5.0% 1.9% 2.5% Revenue 1.3% 40.02.0% 3.0% 50.0 1.5% 20.01.0% 1.0% 0.5% - - 0.0% -1.0% 2019 2020 2021 9M21 9M22 9M21-9M22 growth Contribution +36.8% 2.8% 155,000 t
Slide 31: Outlet Development
Outlet Development 2016-2022 Outlet Development 2022 Outlet Development Target 1-2 20 259 283 292 287 267 259 265 Clinical Labs POC Outlets 5 7 4** 4** 4** 2 4** 11 14 14 12 9 9 9 128 122 1-2 1 118 130 108 98 104 Hospital Labs Specialty Clinic 129 136 143 147* 148* 148* 148* “Prodia not only focus t
Slide 32: 17 New Tests Launched in 9M2022
New Tests Development (since 2018) 47. Jak2 Mutation PREDICTIVE, PREVENTIVE, SCREENING 48. Kidney Stone Analysis (FTIR) DIAGNOSTIC 31. Neurogenomics 49. AMA & ASMA IF 1. NIPT (ProSafe), 16. Rasio s-Flt1/PlGF, 32. Leptospira IgM 50. CT/NG RT PCR (Geneexpert) 2. Telomere Analysis, 17. NBS Amino Acid,
Slide 33: Strategic Partnership to Support Health Tourism
Strategic Partnership to Support Health Tourism Partnership with IHH Healthcare Malaysia: • Prodia as preferred Lab Partner through 152 branches in Indonesia. • Optimizing management of patient to access advanced laboratory testing with high quality standard in Indonesia. • Support Health Tourism de
Slide 34: 9M2022 Revenue (Unaudited)
9M2022 Revenue (Unaudited) Revenue Quarterly Revenue in IDR Billion in IDR Billion 2022 2021 2020 • Revenue in 3Q22 grew FY16-FY21 CAGR +14.3% 9M17-9M22 CAGR +8.7% by 12.9% QtoQ as the 2019 2018 2017 improve of visit 2016 especially from 3Q21, corporate clients 9M21-9M22 752 segment. 2,652 growth: -
Slide 35: 9M2022 Number of Visit and Revenue per Visit
9M2022 Number of Visit and Revenue per Visit Number of Visits (in ‘000) Revenue per Visit (in IDR ‘000) FY16-FY21 CAGR +7.7% 9M17-9M22 CAGR +3.2% FY16-FY21 CAGR +6.1% 9M17-9M22 CAGR +5.3% 9M21-9M22 growth +1.8% 9M21-9M22 growth -22.0% 3,602 3,061 736 742 755 2,482 2,503 2,482 2,571 2,684 2,093 678 6
Slide 36: 9M2022 Test Volume & Test per Visit
9M2022 Test Volume & Test per Visit Test Volume (in ‘000) Test per Visit FY16-FY21 CAGR +6.1% 9M17-9M22 CAGR +4.1% FY16-FY21 CAGR -1.5% 9M17-9M22 CAGR +0.9% 9M21-9M22 9M21-9M22 growth +18.9% growth -7.3% 6.43 19,655 6.42 6.22 6.20 16,520 5.88 6.05 6.08 15,129 15,958 5.80 14,591 13,999 13,726 12,728
Slide 37: Business Performance - Revenue
9M2022 Customer Segments and Testing Types Business Performance - Revenue Walk-in Customers Diversified Doctor Referrals • Individual walk-in patients • Patients referred by doctors Customer Base 31.8% • Out-of-pocket cash • Out-of-pocket cash 32.1% 9M2022 payment payment Revenue Split External Refe
Slide 38: Financial Update
5 FINANCIAL UPDATE 38
Slide 39: 9M2022 EBITDA (Unaudited)
9M2022 EBITDA (Unaudited) EBITDA (in IDR Billion) FY16-FY21 CAGR +34.4% 9M17-9M22 CAGR +24.2% EBITDA Margin 9M21-9M22 growth: -38.1% 50.0% EBITDA declined due 900.0 918.1 45.0% to revenue slow down 800.0 37.4% 40.0% 700.0 745.0 29.2% 35.0% . and some costs 600.0 30.0% increase, meanwhile it 24.3% 34
Slide 40: 9M2022 Gross Profit & Net Income (Unaudited)
9M2022 Gross Profit & Net Income (Unaudited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) FY16-FY21 CAGR +15.5% 9M17-9M22 CAGR +9.8% FY16-FY21 CAGR +47.8% 9M17-9M22 CAGR +22.7% 9M21-9M22 9M21-9M22 growth -22.0% growth -46.2% 621.6 61.9% 60.9% 25.7% 59.7% 61.6% 1,233 962 23.4% 58.4% 58.2
Slide 41: 9M2022 COGS & OPEX (Unaudited)
9M2022 COGS & OPEX (Unaudited) COGS (in IDR Billion) OPEX (in IDR Billion) FY16-FY21 CAGR +12.5% 9M17-9M22 CAGR +7.1% FY16-FY21 CAGR +5.4% 9M17-9M22 CAGR +4.0% 9M21-9M22 9M21-9M22 1,000 growth -18.4% 878 70 1,020 827 growth +4.3% 49.0% 770 746 42 65 800 676 713 50 827 146 45.5% 47.0% 46 30 610 636 6
Slide 42: CAPEX Spending and Dividend Payout
CAPEX Spending and Dividend Payout CAPEX Spending (IDR Billion) Dividend Payout (IDR Billion) 208 Payout Ratio 372.97 168 141 143 129 126 60% 60% 50% 50% 161.25 40% 105.13 30% 87.73 2017 2018 2019 2020 2021 9M 60.32 2022 26.44 CAPEX Plan for 2022: IDR 200-250 Billion 2016 2017 2018 2019 2020 2021 Bu
Slide 43: 9M2022 Financial Summary (Unaudited)
9M2022 Financial Summary (Unaudited) (in IDR Bn) 9M2022 9M2021 Change (in IDR Bn) 9M2022 9M2021 Change Revenue 1,579.9 1,990.7 -20.6% Total Asset 2,540.0 2,611.9 -2.7% Gross Profit 961.5 1,232.9 -22.0% Gross Profit Margin 60.9% 61.9% -100bps Total Equity 2,159.3 2,140.9 -0.8% EBIT 328.0 626.1 -47.6%
Slide 44: Thank You!
THANK YOU! For more information : PT Prodia Widyahusada Tbk investor.relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150 Jakarta 10430, Indonesia www.prodia.co.id 44
PT Prodia Widyahusada — 9M 2022 Earnings Presentation on 6ix